Search Results

There are 7030 results for: content related to: Does androgen-ablation therapy ( AAT ) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?

  1. First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials

    BJU International

    Volume 119, Issue 6, June 2017, Pages: 831–845, Michiel H.F. Poorthuis, Robin W.M. Vernooij, R. Jeroen A. van Moorselaar and Theo M. de Reijke

    Version of Record online : 28 FEB 2017, DOI: 10.1111/bju.13764

  2. You have free access to this content
    Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review

    BJU International

    Volume 116, Issue 1, July 2015, Pages: 30–36, Frank Kunath, Henrik R. Grobe, Gerta Rücker, Edith Motschall, Gerd Antes, Philipp Dahm, Bernd Wullich and Joerg J. Meerpohl

    Version of Record online : 23 MAR 2015, DOI: 10.1111/bju.13026

  3. You have full text access to this OnlineOpen article
    Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer

    BJU International

    Volume 117, Issue 2, February 2016, Pages: 215–225, Jack Schalken and John M. Fitzpatrick

    Version of Record online : 6 JUN 2015, DOI: 10.1111/bju.13123

  4. You have free access to this content
    Non-steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer

    Intervention Review

    The Cochrane Library

    Frank Kunath, Henrik R Grobe, Gerta Rücker, Edith Motschall, Gerd Antes, Philipp Dahm, Bernd Wullich and Joerg J Meerpohl

    Published Online : 30 JUN 2014, DOI: 10.1002/14651858.CD009266.pub2

  5. You have free access to this content
    Avoiding obsolescence in advanced prostate cancer management: a guide for urologists

    BJU International

    Volume 115, Issue 2, February 2015, Pages: 188–197, Neal D. Shore, Lawrence Karsh, Leonard G. Gomella, Thomas E. Keane, Raoul S. Concepcion and E. David Crawford

    Version of Record online : 26 JUN 2014, DOI: 10.1111/bju.12665

  6. You have free access to this content
    Is there an antiandrogen withdrawal syndrome with enzalutamide?

    BJU International

    Volume 115, Issue 3, March 2015, Pages: 373–380, Alejo Rodriguez-Vida, Diletta Bianchini, Mieke Van Hemelrijck, Simon Hughes, Zafar Malik, Thomas Powles, Amit Bahl, Sarah Rudman, Heather Payne, Johann de Bono and Simon Chowdhury

    Version of Record online : 24 OCT 2014, DOI: 10.1111/bju.12826

  7. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors

    The Prostate

    Volume 72, Issue 8, 1 June 2012, Pages: 875–885, Christian Thomas, Latif A. Wafa, Francois Lamoureux, Helen Cheng, Ladan Fazli, Martin E. Gleave and Paul S. Rennie

    Version of Record online : 5 OCT 2011, DOI: 10.1002/pros.21490

  8. You have free access to this content
    Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: Informed scheduling of the bioreductive drug AQ4N improves treatment response

    International Journal of Cancer

    Volume 132, Issue 6, 15 March 2013, Pages: 1323–1332, Louise Ming, Niall M. Byrne, Sarah Nicole Camac, Christopher A. Mitchell, Claire Ward, David J. Waugh, Stephanie R. McKeown and Jenny Worthington

    Version of Record online : 23 NOV 2012, DOI: 10.1002/ijc.27796

  9. Bicalutamide (Casodex®) in the treatment of prostate cancer: History of clinical development

    The Prostate

    Volume 34, Issue 1, 1 January 1998, Pages: 61–72, Geert J.C.M. Kolvenbag, George R.P. Blackledge and Karen Gotting-Smith

    Version of Record online : 7 DEC 1998, DOI: 10.1002/(SICI)1097-0045(19980101)34:1<61::AID-PROS8>3.0.CO;2-N

  10. You have free access to this content
    Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer

    BJU International

    Volume 110, Issue 11, December 2012, Pages: 1729–1735, Mari Nakabayashi, Lilian Werner, Kevin D. Courtney, Geoffrey Buckle, William K. Oh, Glen J. Bubley, Julia H. Hayes, Douglas Weckstein, Aymen Elfiky, Danny M. Sims, Philip W. Kantoff and Mary-Ellen Taplin

    Version of Record online : 29 AUG 2012, DOI: 10.1111/j.1464-410X.2012.11456.x

  11. You have free access to this content
    Enantiomer Selective Glucuronidation of the Non-Steroidal Pure Anti-Androgen Bicalutamide by Human Liver and Kidney: Role of the Human UDP-Glucuronosyltransferase (UGT)1A9 Enzyme

    Basic & Clinical Pharmacology & Toxicology

    Volume 113, Issue 2, August 2013, Pages: 92–102, Laurent Grosse, Anne-Sophie Campeau, Sarah Caron, Frédéric-Alexandre Morin, Kim Meunier, Jocelyn Trottier, Patrick Caron, Mélanie Verreault and Olivier Barbier

    Version of Record online : 20 MAY 2013, DOI: 10.1111/bcpt.12071

  12. Bicalutamide dosages used in the treatment of prostate cancer

    The Prostate

    Volume 39, Issue 1, 1 April 1999, Pages: 47–53, Geert J.C.M. Kolvenbag and Anthony Nash

    Version of Record online : 3 MAR 1999, DOI: 10.1002/(SICI)1097-0045(19990401)39:1<47::AID-PROS8>3.0.CO;2-X

  13. You have free access to this content
    The utility of prostate-specific antigen in the management of advanced prostate cancer

    BJU International

    Volume 112, Issue 5, September 2013, Pages: 548–560, E. David Crawford, Charles L. Bennett, Gerald L. Andriole, Marc B. Garnick and Daniel P. Petrylak

    Version of Record online : 4 JUL 2013, DOI: 10.1111/bju.12061

  14. You have free access to this content
    Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer

    BJU International

    Volume 107, Issue 12, June 2011, Pages: 1923–1929, Vivek K. Wadhwa, Robin Weston and Nigel J. Parr

    Version of Record online : 15 OCT 2010, DOI: 10.1111/j.1464-410X.2010.09726.x

  15. You have free access to this content
    Learning From Estrogen Receptor Antagonism: Structure-Based Identification of Novel Antiandrogens Effective Against Multiple Clinically Relevant Androgen Receptor Mutants

    Chemical Biology & Drug Design

    Volume 79, Issue 3, March 2012, Pages: 300–312, Bing Liu, Guoyan Geng, Rongtuan Lin, Cuiyan Ren and Jian Hui Wu

    Version of Record online : 11 JAN 2012, DOI: 10.1111/j.1747-0285.2011.01290.x

  16. The intracellular and nuclear-targeted delivery of an antiandrogen drug by carrier peptides

    Peptide Science

    Volume 90, Issue 5, 2008, Pages: 595–603, Jason Hodoniczky, Colette G. Sims, Wayne M. Best, Jacqueline M. Bentel and Jacqueline A. Wilce

    Version of Record online : 19 MAR 2008, DOI: 10.1002/bip.20986

  17. Bicalutamide-Associated Fulminant Hepatotoxicity

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 28, Issue 8, August 2008, Pages: 1071–1075, Dr. Cindy L. O'Bryant, Dr. Thomas W. Flaig and Dr. Kenneth J. Utz

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.28.8.1071

  18. THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF THE BICALUTAMIDE (‘CASODEX’) ENANTIOMERS

    Biopharmaceutics & Drug Disposition

    Volume 18, Issue 6, August 1997, Pages: 499–507, I. D. COCKSHOTT, S. D. OLIVER, J. J. YOUNG, K. J. COOPER and D. C. JONES

    Version of Record online : 4 DEC 1998, DOI: 10.1002/(SICI)1099-081X(199708)18:6<499::AID-BDD37>3.0.CO;2-J

  19. You have free access to this content
    Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

    BJU International

    Volume 105, Issue 8, April 2010, Pages: 1074–1081, Peter Iversen, David G. McLeod, William A. See, Thomas Morris, Jon Armstrong, Manfred P. Wirth and on behalf of the Casodex Early Prostate Cancer Trialists’ Group

    Version of Record online : 25 MAR 2010, DOI: 10.1111/j.1464-410X.2010.09319.x

  20. Anti-Tumor Effects and Pharmacokinetics of S-40542, a Novel Non-Steroidal Anti-Androgen, in Mice

    LUTS: Lower Urinary Tract Symptoms

    Volume 5, Issue 1, January 2013, Pages: 44–51, Hiroaki NEJISHIMA, Noriko YAMAMOTO, Mika SUZUKI, Kazuyuki FURUYA, Mitsuo MIMURA and Shizuo YAMADA

    Version of Record online : 25 MAY 2012, DOI: 10.1111/j.1757-5672.2012.00159.x